Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib

Overview of attention for article published in Frontiers in oncology, September 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,675 followers.

RT @FrontOncology: New research: Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on…

17 Sep 2023

Reply Repost Favourite

New research: Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib: Enhancer of zeste homolog 2 (EZH2) and Bruton’s tyrosine kinase (BTK) are both… #oncology

16 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.